Navigation Links
BioMarin to Present at the Goldman Sachs Healthcare Conference
Date:6/2/2009

NOVATO, Calif., June 2 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Goldman Sachs 30th Annual Global Healthcare Conference in New York City on Tuesday, June 9, 2009 at 9:00 a.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
9. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
10. BioMarin to Present at the Morgan Stanley Healthcare Conference
11. BioMarin Announces First Quarter 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... DNA Genotek, a leading provider o... announced that Tepnel Pharmaceutical Services wil... part of its nucleic acid extraction and genotypin...PRWEB) December 1, 2009 -- DNA Genotek , a leadin...ction, today announced that Tepnel Pharmaceutical...
(Date:12/1/2009)... The two humanitarian organization...ams, including biomedical repair technologies. The...e West African country of Togo. , ...th the recent signing of a Memorandum of Understan...formalized a partnership to help develop sustainab...
(Date:12/1/2009)... California waste-to-energy firm c...carbon sequesteration, smallest footprint, salable...ar. , (PRWEB) December 15..., a new innovative organic waste-to-energy process...erence in January. , , ,This biowaste process kn...
(Date:11/30/2009)..., COLUMBUS, Ohio, Nov. 30 The Oh...one of the nation,s first minority business early-...leveland December 3, is called "Transforming the L...ss Early-Stage Capital Summit." It will feature se...ity business leaders and local minority entreprene...
Breaking Biology Technology:Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 2Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 3Mercy Ships and MediSend International Partner to Deliver Hope and Healing 2Mercy Ships and MediSend International Partner to Deliver Hope and Healing 3First Public Showing of Innovative Waste-to-Energy Process 2Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2
...EGAS, March 11 Altogen Biosystems,( http://www.al...rch,services. Located in Las Vegas, NV, Altogen Cu...chnology and pharmaceutical services, including,RN...ly-expressing cell,lines, assay development, scree... company will draw upon their unique experience wi...
...nces Reported in All Three Clinical Programs, Incl...hase II Cancer Program-, TUSTIN, Calif., March 11..., a clinical stage biopharmaceutical,company devel...ancer and,hepatitis C virus (HCV) infection, today... of fiscal year (FY) 2008 ended January 31, 2008. ...
..., China, March 11 /Xinhua-PRNewswire-FirstCall/ --...heets: CBIU), a leading company,within the bionano...,establish long-term strategic cooperative partner...Guangzhou LGLY Advertising LTD is China,s top plan...s well-known for its core senior advertising,profe...
Other Biology Technology:Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 5Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 6Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 7Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 8Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 9Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 10CBIU Signs Agreement with LGLY Advertising LTD 2
(Date:12/1/2009)...t for listening to the radio anymore. They,re used...search from North Carolina State University is rev... shape-shifting antennas that open the door to a h...ty to military deployment. , Modern antennas are...imitations to how far they can be bent and how of...
(Date:11/30/2009)...of gravy and dessert at the holiday table are even...thought. According to a new research report recent...//www.fasebj.org ), a diet that is high in fat and...ly cause our bodies to store too much fat. This me...e already difficult task of converting high-fat an...
(Date:11/30/2009)...lable in German . , The DFG has approved th...entres as of 1 January 2010. This decision was mad...n. The new centres will initially be funded for fo... 20 percent overhead funding for indirect costs wi... research topics range from modern prostheses to p...
Breaking Biology News(10 mins):Shape shifters: Researchers create new breed of antennas 2Happy holidays from the groaning board; Western diets turn on fat genes 2DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 61604 1StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 61604 2StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 61604 3StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 61604 4BioLife Solutions Granted Japanese Biopreservation Patent 14896 1BioLife Solutions Granted Japanese Biopreservation Patent 14896 2BioLife Solutions Granted Japanese Biopreservation Patent 14896 3AMT Provides Business Update for the Third Quarter 2009 14895 1AMT Provides Business Update for the Third Quarter 2009 14895 2AMT Provides Business Update for the Third Quarter 2009 14895 3AMT Provides Business Update for the Third Quarter 2009 14895 4
...er 1, 2007) Damaged or defective genes have long ...he past decade, however, scientists have discovere...f and can cause cancer without any changes in the ...as remained poorly understood. , Researchers in ... now have established a direct causal connection b...
...r chemistry and mineralogy are scientific fields t...ive knowledge and technologies. The boundary of wa...the huge new field of nanoparticle science. , Sci..., from 1 to 100 nanometers, influence natural and ... than similar materials of a larger size. Nanopart...
...stitute of Technology recently received a research...) for the project, Functional Polymers Modified Su...ames) Liang, Associate Professor in the Department...the projects Principal Investigator. , A biofilm i...sibly associated with a surface. Bacteria in biofi...
Other Biology News:DNA methylation shown to promote development of colon tumors 2DNA methylation shown to promote development of colon tumors 3Between water and rock -- a new science 2Between water and rock -- a new science 3Between water and rock -- a new science 4Between water and rock -- a new science 5
Chaps Cell Extract Buffer (10X) from Cell Signaling Technology
Mouse Anti-TGE Virus peplomer Monoclonal Antibody, Unconjugated, Clone 1Q17 from Abcam
Mouse Anti-Human B3GALT2 Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Rabbit Anti-Lck, phospho (Tyr192) Polyclonal Antibody, Unconjugated from Abcam
Biology Products: